Daxor Corporation Awarded New Patent for Remote Monitoring of Blood Volume
November 09 2023 - 7:00AM
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume
measurement technology, today announces that Daxor was recently
granted a patent for a system to provide remote blood volume
monitoring after initial testing with Daxor BVA-100® (Blood Volume
Analyzer) diagnostic.
- This U.S. patent number (US
11,801,002 B2) adds to our existing portfolio that includes more
than a dozen issued and pending-review patents.
- The recently issued patent provides
remote blood volume monitoring through various methods including
wearable devices such as smartwatches for a wide variety of medical
conditions for which volume assessment is recommended.
- This proprietary technology will
help ensure ongoing care is optimized based on the patient’s
evolving blood volume status.
“We are very pleased to add this newly issued
patent to our growing portfolio of intellectual property (IP)
covering innovations in applying blood volume measurement to
specific medical conditions and situations,” said Jonathan
Feldschuh, Daxor’s Chief Scientific Officer. “This patent protects
systems and methods for monitoring patients after an initial blood
volume measurement. This will help ensure that the patient's
continuing care is optimized based on their evolving blood volume
status. The patent discloses various ways this can be accomplished,
including the use of wearable devices such as smartwatches, to
monitor patients with diagnoses including heart failure, critical
care, hypertension, renal failure/dialysis, sepsis, ARDS, surgical
blood loss, and others.”
“Daxor has a robust research and development
program focused on innovation and next-generation technologies,
including approaches to blood volume optimization that rely on
leveraging smart algorithms, computer-assisted clinical decision
support, and novel hardware. These efforts are supported by funding
we have received from the National Institute of Health (NIH) and
United States Department of Defense (DoD) and are part of our
strategy of adding significant intellectual property assets to the
company to fuel future product development,” said Michael
Feldschuh, Chief Executive Officer of Daxor.
Daxor developed and markets the BVA-100
diagnostic, a 98% accurate and objective measurement of blood
volume status and composition, providing clinicians with actionable
results to optimize fluid management and improve patient outcomes
while driving substantial cost savings throughout the healthcare
system.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global
leader in blood volume measurement technology focused on blood
volume testing innovation. We developed and market the BVA-100®
(Blood Volume Analyzer), the only diagnostic blood test cleared by
the FDA to provide safe, accurate, objective quantification of
blood volume status and composition compared to patient-specific
norms. Over 65,000+ tests have been performed at leading hospital
centers across the U.S., enhancing hospital performance metrics in
a broad range of surgical and medical conditions, including
significantly reducing mortality and readmissions in heart failure
and critical care. Daxor has several ongoing trials in the areas of
heart failure treatment with support from the NIH and is under
contract developing analyzers to improve combat casualty care with
the U.S. Department of Defense. Daxor's mission is to advance
healthcare by enabling optimal fluid management with blood volume
analysis. Daxor’s vision is optimal blood volume for all. For more
information, please visit our website at Daxor.com. Sign up to
receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr.
Managing Partner, CORE IR1-516-222-2560brets@coreir.com
Daxor (NASDAQ:DXR)
Historical Stock Chart
From Apr 2024 to May 2024
Daxor (NASDAQ:DXR)
Historical Stock Chart
From May 2023 to May 2024